Protecting Livestock. Improving Human Lives

Safety, Immunogenicity and Antibody Persistence of Rift Valley Fever Virus Clone 13 Vaccine in Sheep, Goats and Cattle in Tanzania

Author: Calvin Sindato, Esron D. Karimuribo, Emmanuel S. Swai, Leonard E.G. Mboera, Mark M. Rweyemamu, Janusz T. Paweska and Jeremy Salt

Year: 2021

About this Publication:

Vaccination is considered to be the best approach to control Rift Valley fever (RVF) in animals and consequently in humans. This study assessed the efficacy and safety of the RVF virus (RVFV) Clone 13 vaccine under field conditions. A vaccine trial was conducted in sheep (230), goats (230), and cattle (140) in Ngorongoro district, Tanzania. Half of each of the animal species were vaccinated and the other half received the placebo. Animals were clinically monitored and bled before vaccination and at days 15, 30, 60, 180 and 360 (+/– 10) post-vaccination to measure Immunoglobulin M (IgM) and IgG antibody responses to RVFV. Survival analysis was conducted using cox-proportional hazard regression model to measure the time until an event of interest had occurred and to compare the cumulative proportion of events over time.

Grant: PLSHL2

Subject Areas: Research and Development

Diseases: Rift Valley Fever



Cattle, Clone 13 vaccine, Goat, Rift valley fever virus, Sheep, Tanzania, immunogenicity, safety


Tanzania, United Republic Of

Download Publication (PDF)